公开(公告)号：US10426814B2

公开(公告)日：2019-10-01

申请号：US15673913

申请日：2017-08-10

申请人： THE PENN STATE RESEARCH FOUNDATION

发明人： Gong Chen ,  Gang-Yi Wu ,  Lei Zhang ,  Jiu-Chao Yin ,  Hana Yeh ,  Ning-Xin Ma ,  Grace Lee

IPC分类号： A61K31/00 ,  A61K38/05 ,  A61K31/519 ,  C12N5/0793 ,  A61K31/4439 ,  A61K31/506

摘要： Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

公开(公告)号：US11116815B2

公开(公告)日：2021-09-14

申请号：US16588054

申请日：2019-09-30

申请人： The Penn State Research Foundation

发明人： Gong Chen ,  Gang-Yi Wu ,  Lei Zhang ,  Jiu-Chao Yin ,  Hana Yeh ,  Ning-Xin Ma ,  Grace Lee

IPC分类号： A61K31/519 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/00 ,  A61K38/05 ,  C12N5/0793

摘要： Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

公开(公告)号：US11850273B2

公开(公告)日：2023-12-26

申请号：US17397927

申请日：2021-08-09

申请人： The Penn State Research Foundation

发明人： Gong Chen ,  Gang-Yi Wu ,  Lei Zhang ,  Jiu-Chao Yin ,  Hana Yeh ,  Ning-Xin Ma ,  Grace Lee

IPC分类号： A61K38/05 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/00 ,  C12N5/0793

CPC分类号： A61K38/05 ,  A61K31/00 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  C12N5/0619 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/08 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00

摘要： Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.

公开(公告)号：US09730975B2

公开(公告)日：2017-08-15

申请号：US14951723

申请日：2015-11-25

申请人： THE PENN STATE RESEARCH FOUNDATION

发明人： Gong Chen ,  Gang-Yi Wu ,  Lei Zhang ,  Jiu-Chao Yin ,  Hana Yeh ,  Ning-Xin Ma ,  Grace Lee

IPC分类号： A61K38/05 ,  A61K31/00 ,  C12N5/079 ,  C12N5/0793 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/506

CPC分类号： A61K38/05 ,  A61K31/00 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  C12N5/0619 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/727 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2506/08

摘要： Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.